B. Riley Securities Rates Whitehawk Therapeutics (WHWK) buy
Analyst Yuan Zhi maintains a buy rating on Whitehawk Therapeutics while keeping a $10.00 price target on the clinical-stage biotech stock, a 140.38% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B. Riley Securities rated Whitehawk Therapeutics, Inc. ($WHWK) "buy" with a $10 price target on June 25, 2026.
Since the rating, $WHWK is up 1.9% after 1 week, down 10.0% after 1 month and down 29.7% to date (from the $4.11 close on Jun 25, 2026).
WHWK
Whitehawk Therapeutics, Inc.
Key Points
- B. Riley Securities reaffirmed its buy rating on Whitehawk Therapeutics on June 25, 2026, setting a $10.00 price target.
- B. Riley Securities's $10 price target implies 140.38% upside from Whitehawk Therapeutics, Inc.'s ($WHWK) current $4.16 share price.
- Whitehawk Therapeutics shares recently traded at $4.16, sitting well below the analyst's target price.
- The broader analyst community holds a consensus buy rating on Whitehawk Therapeutics with a mean target price of $7.50.
Get $WHWK trade alerts by text
We text you when insiders, Congress or big funds trade $WHWK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Whitehawk Therapeutics, Inc. alert may contain errors. Disclosures
B. Riley Securities Affirms Whitehawk Stance
B. Riley Securities analyst Yuan Zhi has chosen to keep a buy rating on Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK), according to an update on June 25, 2026. The firm maintained its price target at $10.00. This call puts the target well above where the shares currently change hands, creating a wide gap for investors to watch.
B. Riley Securities vs. the S&P 500
Hypothetical returns from B. Riley Securities's disclosed trades, not real profit or advice. How we model this.
Stock Trades Near Midpoint of 52-Range
Whitehawk Therapeutics shares recently traded at $4.16 on Thursday, sitting comfortably between its 52-week low of $1.82 and its 52-week high of $5.50. The stock trades close to its 50-day moving average of $4.29 while holding above its 200-day moving average of $3.71. With a spot price of $4.16, the $10.00 target from B. Riley Securities leaves a large potential runway if the biotech firm can hit its goals.
$WHWK price target
Whitehawk Therapeutics, Inc. daily closes and this analyst's $10 target. Not advice.
Analysts Set New Price Targets
Other Wall Street firms have also chimed in on Whitehawk Therapeutics recently. Stifel initiated coverage on the stock with a buy rating and a $9.00 target on October 1, 2026. Earlier in the summer, Leerink Partners started coverage with an outperform rating and a $9.00 target on July 13, 2026. Across six analyst opinions tracked by the market, the stock holds a consensus recommendation of buy. Those opinions combine for a mean price target of $7.50, with a high target of $10.00 and a low target of $4.00.
What Whitehawk Therapeutics Does
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company based in Morristown, New Jersey. The firm develops technologies focused on tumor biology to improve cancer treatments, featuring three next-generation antibody drug conjugate portfolios in its pipeline. The company employs a small team of 32 people and operates in the biotechnology sector.
Looking Ahead for Whitehawk
Investors will want to keep an eye on upcoming corporate updates and the company's next scheduled earnings report on November 5, 2026. Analyst coverage and price targets will likely shift as the clinical pipeline moves forward and the company reports on its ongoing cancer research milestones.
Related Filing Alerts
Source: B. Riley Securities's rating change on $WHWK (Jun 25, 2026). Written by software, not financial advice. How we make alerts